XENE Xenon Pharmaceuticalsdata gap · 30% coveragelimited data
Health Care · Pharmaceutical Preparations · close $33.49 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Xenon Pharmaceuticals (XENE) has a ThetaGrade House Rating of 29/100 (grade F), ranking #147 of 150 in Health Care. Its strongest pillars are balance sheet (95) and cash flow (1); its weakest is growth (0). Data gap: 10 factors without usable data, so 30% of the method weight is covered. TTM revenue growth is -100.0% and operating margin —.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, EPS growth YoY (TTM), Revenue acceleration, Operating margin, 4Q gross-margin change, Net debt / EBITDA, Interest coverage, P/E (inverted), EV/Sales (inverted). Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 30% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→50.0%) · 0| Revenue growth YoY (TTM) (50.0%) | -100.0% | 0 |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (0.0%)data gap | — | — |
Profitability
weight 18.5% · no data · —| Operating margin (0.0%)data gap | — | — |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% (→30.0%) · 95| Net debt / EBITDA (0.0%)data gap | — | — |
| Current ratio (30.0%) | 21.02 | 95 |
| Interest coverage (0.0%)data gap | — | — |
Cash flow
weight 12.33% (→20.0%) · 1| FCF margin (10.0%) | -3732.2% | 2 |
| FCF yield (10.0%) | -8.6% | 0 |
Valuation
weight 12.33% · no data · —| P/E (inverted) (0.0%)data gap | — | — |
| EV/Sales (inverted) (0.0%)data gap | — | — |
Technicals (EOD)
| RSI(14) | 20.7 |
| EMA 9 / 21 | 35.28 / 39.14 |
| 200-day SMA | 52.66 |
| Volume vs 20d avg | 0.35× |
| 20-day return | -41.6% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- EXITFundamental miss: revenue growth negative YoY
- EXITBalance-sheet stress: negative free cash flow (latest FY)
- WATCHTrend: close below 200-day average
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerIncludingAssessedTax · Operating income: OperatingIncomeLoss · D&A: DepreciationAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close.
Get rating changes like XENE's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is XENE's House Rating?
- XENE scores 29 out of 100 (grade F) as of 2026-10-16, ranking #147 of 150 Health Care stocks we cover.
- What do analysts say about XENE?
- We do not have enough analyst-sentiment data to score this stock.
- When does XENE report earnings next?
- We do not have a reliable estimate for XENE's next earnings date (irregular SEC filing history); a rough window is 2026-10-25 to 2026-11-10. Check the company's investor-relations page.
- Is XENE a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology